PARP inhibitors

Big Pharma-Backed Ribon Therapeutics Shuts Down Business Operations
BioSpace
Mon, 08/5/24 - 11:21 am
Ribon Therapeutics
AbbVie
JNJ
Novartis
Pfizer
PARP inhibitors
AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027
Biopharma Reporter
Thu, 04/25/24 - 11:36 am
AstraZeneca
PARP inhibitors
Merck
Lynparza
ovarian cancer
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Mon, 10/30/23 - 11:58 am
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
J&J joins PARP rivals with narrow FDA clearance in prostate cancer
BioPharma Dive
Mon, 08/14/23 - 10:18 am
JNJ
Akeega
BRCA-mutated prostate cancer
PARP inhibitors
FDA
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Fierce Pharma
Thu, 06/22/23 - 10:12 am
Pfizer
FDA
prostate cancer
Talzenna
AstraZeneca
PARP inhibitors
Merck
J&J claims first approval for PARP combo Akeega
Pharmaphorum
Mon, 04/24/23 - 10:22 am
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Wed, 04/12/23 - 11:39 am
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
BioPharma Dive
Sun, 03/5/23 - 03:08 pm
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
Sun, 02/26/23 - 10:14 pm
JNJ
Akeega
prostate cancer
PARP inhibitors
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
BioSpace
Sun, 11/13/22 - 07:07 pm
GSK
ovarian cancer
Zejula
PARP inhibitors
FDA
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
Endpoints
Tue, 10/4/22 - 11:06 am
Pfizer
Xtandi
Talzenna
PARP inhibitors
Medivation
clinical trials
prostate cancer
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
Seeking Alpha
Wed, 09/21/22 - 08:01 pm
Merck KGaA
Nerviano Medical Sciences
NS-293
PARP inhibitors
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
AZ aims at Pfizer, GSK with potential new PARP cancer drug
Pharmaforum
Wed, 04/14/21 - 09:28 am
AstraZeneca
PARP inhibitors
Pfizer
GSK
cancer
Lynparza
KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor
Fierce Biotech
Sun, 10/25/20 - 11:28 pm
KSQ Therapeutics
PARP inhibitors
ovarian cancer
breast cancer
KSQ-4279
Merck
AstraZeneca
Lynparza
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
Thu, 10/24/19 - 10:08 am
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Fierce Pharma
Sat, 10/12/19 - 12:32 pm
Clovis Oncology
Rubraca
NICE
UK
PARP inhibitors
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
Tue, 10/1/19 - 10:29 am
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
Sun, 09/29/19 - 11:57 am
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula

Pages